3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Withdrawn
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Endocrine
1
Conditions
Thyroid Neoplasms
2
Thyroid Carcinoma, Anaplastic
2
Head and Neck Neoplasms
1
Interventions
Paclitaxel
4
fosbretabulin
3
Radiotherapy
3
selpercatinib
2
Filgrastim
2
Everolimus
2
Doxorubicin
2
Cisplatin
2
vandetanib
1
tumor necrosis factor-alpha, CNGRC fusion protein, human
1
sargramostim
1
repotrectinib
1
pralsetinib
1
pentetreotide
1
pegfilgrastim
1
mercaptoundecahydrododecaborate
1
gallium Ga 68 dotatate
1
fostamatinib
1
entrectinib
1
combretastatin
1
alectinib
1
aldesleukin
1
Triiodothyronine
1
Thyrotropin Alfa
1
Thyrotropin
1
Thalidomide
1
Tamoxifen
1
Semaxinib
1
Rosiglitazone
1
Radiofrequency Ablation
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Head and Neck Neoplasms
×
combretastatin
×
Endocrine
×
Clear all
NCT01701349
2014-05-01
FACT2
Mateon Therapeutics
Phase 3
Withdrawn